Kenneth D. Polin

Releviate Therapeutics LLC is a bio-pharmaceutical company that was founded in 2020. The private company is based in San Diego, CA. Releviate Therapeutics addresses the needs of patients suffering from neuropathic pain by deploying specific human monoclonal antibodies to inactivate certain matrix metalloproteinases (MMP-9 and MMP-14) and potentially improve patient outcomes. The company's first-in-class therapy directly targets pain with antibodies whose development is rooted in actual pain pathophysiology. The therapy is designed to reverse underlying pathophysiology leading to neuropathic pain, and initial indications address small fiber neuropathy and diabetic neuropathy. The company's approach is very similar to Abbvie's Humira, inactivating the master-switch that causes chronic pain. Sergey Sikora, Robert S. Sullivan, and Jackie Townsend Konstanturos founded the company, and Sergey Sikora has been the CEO since 2020.

Releviate Therapeutics LLC is a bio-pharmaceutical company that was founded in 2020. The private company is based in San Diego, CA. Releviate Therapeutics addresses the needs of patients suffering from neuropathic pain by deploying specific human monoclonal antibodies to inactivate certain matrix metalloproteinases (MMP-9 and MMP-14) and potentially improve patient outcomes. The company's first-in-class therapy directly targets pain with antibodies whose development is rooted in actual pain pathophysiology. The therapy is designed to reverse underlying pathophysiology leading to neuropathic pain, and initial indications address small fiber neuropathy and diabetic neuropathy. The company's approach is very similar to Abbvie's Humira, inactivating the master-switch that causes chronic pain. Sergey Sikora, Robert S. Sullivan, and Jackie Townsend Konstanturos founded the company, and Sergey Sikora has been the CEO since 2020.

Releviate Therapeutics LLC is a bio-pharmaceutical company that was founded in 2020. The private company is based in San Diego, CA. Releviate Therapeutics addresses the needs of patients suffering from neuropathic pain by deploying specific human monoclonal antibodies to inactivate certain matrix metalloproteinases (MMP-9 and MMP-14) and potentially improve patient outcomes. The company's first-in-class therapy directly targets pain with antibodies whose development is rooted in actual pain pathophysiology. The therapy is designed to reverse underlying pathophysiology leading to neuropathic pain, and initial indications address small fiber neuropathy and diabetic neuropathy. The company's approach is very similar to Abbvie's Humira, inactivating the master-switch that causes chronic pain. Sergey Sikora, Robert S. Sullivan, and Jackie Townsend Konstanturos founded the company, and Sergey Sikora has been the CEO since 2020.

Releviate Therapeutics LLC is a bio-pharmaceutical company that was founded in 2020. The private company is based in San Diego, CA. Releviate Therapeutics addresses the needs of patients suffering from neuropathic pain by deploying specific human monoclonal antibodies to inactivate certain matrix metalloproteinases (MMP-9 and MMP-14) and potentially improve patient outcomes. The company's first-in-class therapy directly targets pain with antibodies whose development is rooted in actual pain pathophysiology. The therapy is designed to reverse underlying pathophysiology leading to neuropathic pain, and initial indications address small fiber neuropathy and diabetic neuropathy. The company's approach is very similar to Abbvie's Humira, inactivating the master-switch that causes chronic pain. Sergey Sikora, Robert S. Sullivan, and Jackie Townsend Konstanturos founded the company, and Sergey Sikora has been the CEO since 2020.